| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Pre-Funded Warrants to Purchase 6,500,000 Shares of Common Stock |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION October 27, 2026 ATI-052 Phase 1b Primary Analysis Results Atopic Dermatitis and Asthma |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and Leerink Partners LLC and Cantor Fitzgerald & Co., as sales agents and/or principals (collectively the “Agents,” and each individually an “Agent”), are parties to tha... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, Aclaris Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s defi... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - |
| 28 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus April 28, 2026 |
| 11 Mar 2026 |
8-K: Regulation FD Disclosure
On March 10, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 5.7 million shares of its common stock, for aggregate gross proceeds of $20.0 million pursuant to the Company’s amended and restated sales agreement with Leerink Partners... |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure
From March 2, 2026 through March 9, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 12.7 million shares of its common stock, for aggregate gross proceeds of $39.8 million pursuant to the Company’s amended and restated sales agreeme... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Corporate Overview January 2026 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION |
| 06 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
ATI-052: Anti-TSLP x IL-4Rα Bispecific Antibody Program Highly Potent and Bioactive Investigational Product Candidate January 6, 2026 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an ... |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
Patient Focused Innovation Developing Therapeutic Franchises to Address Gaps in Important I&I Diseases 2025 R&D Day October 14, 2025 |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - |
| 29 Jul 2025 |
8-K: Regulation FD Disclosure; Other Events
2 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private S... |
| 30 Jun 2025 |
8-K: Regulation FD Disclosure
Corporate Overview June 2025 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION |
| 05 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
(a)Successor to Prior Plan. This Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan (as it may be amended from time to time, the “Plan”) is intended as the successor to the Aclaris Therapeutics, Inc. 2015 Equity Incentive Plan, as ame... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - |
Loading...